36,868 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Van ECK Associates Corp

Van ECK Associates Corp bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, HoldingsChannel reports. The institutional investor bought 36,868 shares of the medical equipment provider’s stock, valued at approximately $2,960,000.

Other hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC acquired a new position in Lantheus in the fourth quarter valued at approximately $407,000. M&T Bank Corp acquired a new position in shares of Lantheus in the 4th quarter valued at $320,000. Charles Schwab Investment Management Inc. boosted its position in shares of Lantheus by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider’s stock worth $52,077,000 after purchasing an additional 7,590 shares during the last quarter. Principal Securities Inc. acquired a new stake in shares of Lantheus during the fourth quarter worth $28,000. Finally, Versor Investments LP bought a new stake in Lantheus in the fourth quarter valued at about $506,000. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LNTH shares. JMP Securities reduced their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Truist Financial decreased their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday. They issued a “buy” rating and a $175.00 target price for the company. B. Riley lifted their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Finally, Leerink Partners upped their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Insider Activity

In related news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The disclosure for this sale can be found here. Insiders have sold 41,193 shares of company stock worth $3,949,202 over the last ninety days. Insiders own 1.50% of the company’s stock.

Lantheus Price Performance

LNTH stock opened at $105.34 on Friday. The stock has a 50-day moving average price of $102.18 and a two-hundred day moving average price of $80.95. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a market cap of $7.30 billion, a PE ratio of 16.08 and a beta of 0.51. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.40 earnings per share. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.03 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.